Trigeminal Neuralgia Treatment Market By Treatment (Drug Based, Surgery) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025
This report on global trigeminal neuralgia treatment market studies various drugs used for treatment of trigeminal neuralgia along with pipeline analysis of upcoming potential drugs. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. According to the International Association for the Study of Pain the incidence of Trigeminal Neuralgia is 12 per 100,000 persons per year. The etiology includes the compression of blood vessels, degeneration of arteries, myelin sheath infiltration and idiopathy. Trigeminal neuralgia is most commonly seen after the age of 40 years more common in female. Thus, drug pipeline of trigeminal neuralgia treatment market comprises potential drugs which are more target-specific and possess innovative properties.
For the purpose of this study, the various treatment types studied includes drug based therapy and surgical procedures; further, drug based therapy are segmented as anticonvulsant drugs, NSAIDs, and opioids. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
The pipeline analysis for trigeminal neuralgia treatment market comprises projected market sales of Phase III drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (chemical-based or biological), sponsor, depicted peak sales by leading market experts and other factors.
The geographic segmentation of the global trigeminal neuralgia treatment market is performed for the regions North America, Europe, Asia-Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. The etiology includes the compression of blood vessels, degeneration of arteries, myelin sheath infiltration and idiopathic. According to American Association of Neurological Surgeons150,000 people are diagnosed with Trigeminal Neuralgia. Trigeminal neuralgia is most commonly seen after the age of 40 years. Based on the treatment type, the trigeminal neuralgia treatment market is segmented into:
- Drug-based
- Anticonvulsant
- NSAIDs
- Opioids
- Surgery
- Rhizotomy
- Stereotactic radiosurgery
- Micro vascular decompression
According to market experts, drug based therapy is increasingly used to treat in developed markets, but application is still low in emerging markets, carbamazepine being the only approved drug in the market which is considered as the first line therapy followed by NSAIDs and opioids. However, the drug related side effects are high, so patients are opting for various types of surgical procedures for the treatment of trigeminal neuralgia like micro-vascular decompression, rhizotomy, and stereotactic radiosurgery. In base year 2016, drug based therapy accounted for the major market share in the treatment around 71% followed by surgical procedures which accounts for remaining 29% for patients those are not responding to drug therapy. During the forecast period 2017 – 2025 drug based therapy are expected to project a significant growth. The key factors assisting the segment growth comprises patient-supportive reimbursement policies that has assisted the increased use drug based therapy in developed markets, rise in aging population coupled with growing public awareness, and technological advancements in the surgical procedures.
For the purpose of this study, the global trigeminal neuralgia treatment market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
North America was observed as the largest market for trigeminal neuralgia treatment in the base year 2016 due to rise in aging population and technological advancement in diagnostic tests. Europe is expected to be the second largest market due to rising public awareness, healthcare infrastructure and penetration of new technologies. According to American Association of Neurological Surgeons150,000 people are diagnosed with Trigeminal Neuralgia. Growth in Asia-Pacific in trigeminal neuralgia treatment market is attributed by factors like rising prevalence of neuropathic pain diseases, increasing investments in R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care and aging population are going to fuel the rapid growth of Trigeminal neuralgia disease treatment market in Latin America and Middle East and Africa region in the near future.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Trigeminal Neuralgia Treatment Market Portraiture
2.2 Global Trigeminal Neuralgia Treatment Market, by Treatment, 2016 (US$ Mn)
2.3 Global Trigeminal Neuralgia Treatment Market, by Geography, 2016 (Value %)
Chapter 3 Global Trigeminal Neuralgia Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Growing prevalence of chronic pain disorders have generated demand for Trigeminal Neuralgia Treatment
3.2.2 Rise in aging population and public awareness have generated demand for Trigeminal Neuralgia Treatment
3.3 Market Restraints
3.3.1 Insufficient funding in emerging markets and high cost involved in treatment of Trigeminal Neuralgia
3.4 Market Opportunities
3.4.1 Improved Healthcare expenditure due to patient oriented reimbursement policies and tapping market of unmet medical needs
3.5 Porter's Five Forces Model
3.6 Attractive Investment Proposition
3.7 Market Competition Assessment: Trigeminal Neuralgia Treatment, by Key Players
Chapter 4 Global Trigeminal Neuralgia Treatment Market, By Type of Treatment
4.1 Introduction
4.2 Drug Based
4.2.1 Anticonvulsant
4.2.2 NSAIDs
4.2.3 Opioids
4.3 Surgery
4.3.1 Rhizotomy
4.3.2 Stereotactic radiosurgery
4.3.3 Micro vascular decompression
Chapter 5 Global Trigeminal Neuralgia Treatment Market, By Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Latin America
5.6 Middle East and Africa
Chapter 6 Company Profiles
6.1 Allergan Plc
6.1.1 Allergan Plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.2 Biogen, Inc.
6.2.1 Biogen, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.3 Kineta Inc.
6.3.1 Kineta Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.4 Merz Pharma GmbH & Co.
6.4.1 Merz Pharma GmbH & Co.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.5 Trigemina Inc.
6.5.1 Trigemina Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.6 Abbott Laboratories
6.6.1 Abbott Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.7 Pfizer Inc.
6.7.1 Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.8 GlaxoSmithKline Plc.
6.8.1 GlaxoSmithKline Plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.9 Novartis
6.9.1 Novartis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.10 Shire
6.10.1 Shire: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 1 Global Trigeminal Neuralgia Treatment Market, By Treatment, 2015-2025 (US$ Mn)
TABLE 2 Drug based treatment market for Trigeminal Neuralgia, 2015-2025 (US$ Mn)
TABLE 3 Surgery based treatment market for Trigeminal Neuralgia, 2015-2025 (US$ Mn)
TABLE 4 Global Trigeminal Neuralgia Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 Allergen Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 6 Biogen Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 7 Kineta Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments
TABLE 8 Merz Pharma GmbH & Co.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 9 Trigemina Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Development
TABLE 10 Abbot Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 11 Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 12 GlaxoSmithkline Plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Novartis : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 14 Shire : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
FIG. 1 Trigeminal Neuralgia Treatment Market: Research Methodology
FIG. 2 Global Trigeminal Neuralgia Treatment Market, by Treatment 2016 (US$ Mn)
FIG. 3 Global Trigeminal Neuralgia Treatment Market, by Geography, 2016 (Value %)
FIG. 4 Porter's Five Forces Model: Trigeminal Neuralgia Treatment Market
FIG. 5 Attractive Investment Proposition, by Geography,2016
FIG. 6 Market Positioning of Key Trigeminal Neuralgia Treatment Market Players, 2016
FIG. 7 Anticonvulsant Market for Trigeminal Neuralgia Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 NSAIDs Market for Trigeminal Neuralgia Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Opioids Market for Trigeminal Neuralgia Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Rhizotomy Market for Trigeminal Neuralgia Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 Rhizotomy Market for Trigeminal Neuralgia Treatment, 2015 – 2025 (US$ Mn)
FIG. 12 Rhizotomy Market for Trigeminal Neuralgia Treatment, 2015 – 2025 (US$ Mn)
FIG. 13 North America Trigeminal Neuralgia Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 14 Europe Trigeminal Neuralgia Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 15 Asia-Pacific Trigeminal Neuralgia Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 16 Latin America Trigeminal Neuralgia Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 17 Middle East and Africa Trigeminal Neuralgia Treatment Market , 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)